WIC-APAC 2026

Chief	Bernard A. Fox, PhD Laboratory of Molecular and Tumor Immunology, Earle A. Chiles Research Institute, Providence Cancer Institute TBA
SITC President	James L. Gulley, M.D., PhD National Cancer Institute, NIH, USA TBA
JITC Editor-in-Chief	Michael T. Lotze, M.D. University of Pittsburgh School of Medicine, USA TBA
WIC-APAC Co-Founder	Dr. Joe Yeong, MBBS, PhD, FRCPath (UK) Director of ImmunoPathology Singapore General Hospital Dr. Joe Yeong’s main research focus is to understand and overcome the resistance of cancer immunotherapy, by using advanced technologies and AI. As an immunopathologist, his key vision is to bridge immunologists and pathologists. He is a pioneer in spatial technologies, translated assays to clinic, and has published >130 papers in the field (Top 2% Scientist) (>100 invited talks internationally). His works on cancer immunology are included in multiple National & international funded studies as well as industry sponsored projects (>20 million dollars since 2017). He served as a committee member in the World Immunotherapy Council, Society for Immunotherapy of Cancer (SITC) and is one of the organizers for its 2019, 2023 & 2025 WIC Global Symposium as well as multiplex IF expert consensus meetings. He also serves as one of the founding-Program Chair of one of the largest AI medical Imaging conferences, CLINICAI-MICCAI and serves as founding board member of MICCAI SIG-ComPath. He is also having editorial roles of Nature Springer, JITC, JCO (ASCO) and World Scientific (Chief Editor). He serves as a Secretary (Executive) in Singapore Society of Oncology – Cancer Immunotherapy Consortium, Co-lead in Education/Diagnostic of SingHealth Duke-NUS Cell Therapy Centre as well as Advisor (Spatial Technology), Cancer Discovery Hub, National Cancer Centre. In 2023, he co-founded World Immunotherapy Council Asian Chapter for promoting tumor immunology and advancing cancer immunotherapy education, information and research across Asia. He is also a regular reviewer for top journal such as JITC, Mod Path, Lancet and Nature.
WIC-APAC 2026 Taiwan Chair	Dr. John Wen-Cheng CHANG, MD Medical Oncologist / Professor Linkou Chang Gung Memorial Hospital Honorary President, TSITC Chair, International Affairs Committee, TOS TBA

Co-hosting Societies

TSITC President

Dr. Peter Chiao-En WU, MD, PhD

Medical Oncologist / Professor
Linkou Chang Gung Memorial Hospital
New Taipei Municipal TuCheng Hospital

TOS President

Dr. Jen-Shi CHEN, MD

Medical Oncologist / Professor
Linkou Chang Gung Memorial Hospital

Dr. Chen, born in Taiwan, is a medical professional with extensive training and experience. He graduated from China Medical University in Taichung, Taiwan, and completed his residency and medical oncology training at Linkou Chang Gung Memorial Hospital (CGMH). In 1995, he enhanced his expertise through clinical training at MD Anderson Cancer Center.

He currently serves as Professor of the Department of Hematology-Oncology at Linkou CGMH and Chang Gung University. Dr. Chen has held several leadership positions, including Chairman of the Academic Committee of the Taiwan Oncology Society (2013–2015), Secretary General of the Organizing Committee of the Asian Society of Clinical Oncology (2014), and Chairman of the Medical Oncology Committee of the Taiwan Oncology Society (2015–2017). In 2023, he was appointed President of the Taiwan Oncology Society.

Dr. Chen is a member of multiple professional and cancer research organizations, including the American Society of Clinical Oncology, the European Society for Medical Oncology, the Taiwan Society of Internal Medicine, the Taiwan Cooperative Oncology Group, and the Taiwan Clinical Oncology and Taiwan Oncology Societies. His primary research interests include clinical trials for cancers of the upper gastrointestinal tract, pancreatic-biliary cancers, gastrointestinal stromal tumors (GIST), neuroendocrine tumors, and quality of life in oncology care.

He has participated in numerous international clinical studies and served as Principal Investigator (PI) for several PI-initiated studies. To date, Dr. Chen has authored over 220 peer-reviewed articles. Notably, he co-authored studies, including the Sunitinib study for pancreatic neuroendocrine tumors published in the *New England Journal of Medicine (2011), the S-1 (GEST) study for pancreatic cancer in the Journal of Clinical Oncology (2013), and the Nivolumab ATTRACTION-2 study for gastric cancer in The Lancet (2017). Most recently, his contributions include the TOPAZ-1 study on first-line treatment for biliary tract cancer and the Taiwan Pancreas Society's guidelines on systemic treatment for pancreatic cancer in 2023. He is currently involved in several novel anti-cancer drugs studies.

TSITC General Secretary